Dr. Reddy’s Files First Paragraph IV ANDA Against Teva’s 40mg Copaxone

Drug Industry Daily
A A
Indian generics firm Dr. Reddy’s has filed the first patent challenge against Teva’s blockbuster multiple sclerosis drug Copaxone’s 40 mg, introducing a new chapter into the Israeli drugmaker’s efforts to protect its multibillion dollar product.

To View This Article:

Login

Subscribe To Drug Industry Daily